EULAR Conference 2024
What’s On-Board
The EULAR Conference 2024, an annual event organized by the European Alliance of Associations for Rheumatology, promises to be a pivotal gathering for professionals in the field of rheumatology. This conference will feature a diverse array of presentations, workshops, and networking opportunities aimed at advancing the understanding and treatment of rheumatic diseases. Attendees can expect to engage with the latest research findings, innovative therapies, and clinical practices presented by leading experts.
The DelveInsight team will have a great chance to broaden their professional connections with industry specialists worldwide. Our team members can participate in enlightening seminars, rheumatology workshops, and educational sessions tailored to the needs and interests of clinical rheumatologists and researchers.
DelveInsight will recognize the many scientific abstracts presented at the EULAR Congress, showcasing the latest advancements and findings in rheumatology clinical trials. These abstracts feature groundbreaking research on new therapies that could dramatically transform treatment methods for patients.
Schedule a one-to-one meeting with our experts at EULAR 2024 from June 12 - June 15, 2024.
Join us simply by filling up the form upright.
Share:
DelveInsight intends to provide useful reports that are relevant to the rare disease market. Our analysts monitor competing products’ developmental, regulatory, and commercial milestones. It comprises features such as conference evaluation and company and R&D development evaluation to carry out the desired development of a rheumatological product for commercial purposes dealing with the client’s area of interest.
Our multidimensional, purposeful, and credible consultancy services will aid in the acceleration of hematology product services, including aspects such as congress intelligence, conference coverage, CI asset/indication tracking, brand presence and penetration assessment, drug therapy uptake, and diagnostic landscape assessment to overcome several rheumatology market challenges.
We stand out from the crowd by hiring a specialized primary Competitive Intelligence research team. It constitutes analysts, senior analysts, and managers. Our CI force provides the finest opportunity and most accurate intelligence to be obtained and shared with our allies. Furthermore, extraordinary data collecting with the primary purpose of acquiring best-in-class intelligence and offering analysis to our partners’ consulting goals.
Our research and development analyst understands the rheumatology domain to make value-based judgments and assist clients in achieving superior rheumatology R&D outcomes. The path of each rheumatological medicine through pre-clinical and clinical development is completed by evaluating the same factors as other candidates currently in the field. Similar is done for the rheumatology drugs as well. DelveInsight’s insightful rheumatology reports clarify uncertainties and challenge blind spots to provide the organization with timely intelligence.
DelveInsight's Rheumatological Pipeline Assessment promises a comprehensive picture of emerging therapies, clinical trials, and highlights of the rheumatology therapeutics landscape in a report format. Our Pipeline Assessment report type, which includes rheumatology-ready reports already available in our Report Store, gives insights across treatments, MoAs, Drugs, APIs, and Launch Insights of therapies in late-stage development to provide awareness of their launch timelines and strategies.
Share:
We welcome you to discuss your business-related concerns, and we can together find the best possible solution to help you proceed further in the rheumatology market.
Share:
The EULAR 2024 conference and exhibition will take place in Vienna, Spain, from June 12 - 15, 2024
Share:
Counting Down
-